<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05085626</url>
  </required_header>
  <id_info>
    <org_study_id>BC-Fluzoparib</org_study_id>
    <nct_id>NCT05085626</nct_id>
  </id_info>
  <brief_title>Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer</brief_title>
  <official_title>An Open, Single-center, Cohort Clinical Study of Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive and HER2-negative Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to include 40 patients with HER2-negative advanced breast cancer to&#xD;
      receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to&#xD;
      observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or&#xD;
      chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR(objective response rate)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>through study completion, an average of 6 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced HER2 Negative Breast Carcinoma</condition>
  <condition>HRD+Breast Cancer</condition>
  <arm_group>
    <arm_group_label>fluzoparib+chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.&#xD;
Chidamide: It is recommended to take 20 mg (4 tablets) twice a week, with an interval of no less than 3 days between doses (such as Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), for 30 minutes. Until disease progression or intolerable to patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluzoparib+camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluzoparib: 150 mg twice daily (morning and evening) for 21 consecutive days as a cycle until disease progression or intolerance.&#xD;
Camrelizumab: 200 mg IV drip over approximately 30 minutes (no less than 20 minutes and no more than 60 minutes) on Day 1 of each 3-week treatment cycle until disease progression or intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluzoparib+chidamide</intervention_name>
    <description>Arms A will be treated with fluzoparib in combination with cedaramide</description>
    <arm_group_label>fluzoparib+chidamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluzoparib+camrelizumab</intervention_name>
    <description>Arms B will be treated with fluzoparib in combination with camrelizumab</description>
    <arm_group_label>fluzoparib+camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. histologically confirmed initial stage IV breast cancer or recurrent metastatic breast&#xD;
             cancer; advanced treatment stage received at least 1 line of chemotherapy but no more&#xD;
             than 2 lines of chemotherapy; hormone receptor-positive patients received at least one&#xD;
             endocrine therapy in advanced treatment stage, or the investigator judged that they&#xD;
             were not suitable for endocrine therapy; and patients with hormone receptor-positive&#xD;
             advanced breast cancer who progressed within 2 years of adjuvant endocrine therapy.&#xD;
&#xD;
          2. histologically confirmed invasive HER2-negative breast cancer (specific definition:&#xD;
             HER20-1 + or HER2 2 + by immunohistochemistry but negative or no amplification by FISH&#xD;
             or CISH, following the 2018 version of the ASCO-CAPHER2 guidelines for negative&#xD;
             interpretation);&#xD;
&#xD;
          3. central confirmation of HRD positivity, known germline BRCA and/or systemic BRCA&#xD;
             mutation status is allowed to be preferred.&#xD;
&#xD;
          4. age 18-70 years&#xD;
&#xD;
          5. According to RECIST 1.1, at least one measurable lesion is present;&#xD;
&#xD;
          6. ECOG score: 0-2; expected survival more than 12 weeks;&#xD;
&#xD;
          7. Previous treatment with immune checkpoint inhibitors, PARP inhibitors and HDAC&#xD;
             inhibitors (including chidamine, romidepsin, vorinostat, benirestat, parastat, etc.);&#xD;
&#xD;
          8. All acute toxicities caused by previous anti-tumor treatment return to the level&#xD;
             specified in the inclusion/exclusion criteria (except alopecia and other toxicities&#xD;
             that are considered by the investigator to pose no safety risk to the subjects);&#xD;
&#xD;
          9. Female subjects of childbearing potential need to use a medically recognized&#xD;
             contraceptive measure during the study treatment and at least 3 months after the last&#xD;
             use of the study drug;&#xD;
&#xD;
         10. Patients with known hormone receptor status;&#xD;
&#xD;
         11. Main organ function is basically normal, and meet the following conditions:&#xD;
&#xD;
               1. Blood routine examination criteria need to meet: HB ≥ 90 g/L (14 without blood&#xD;
                  transfusion); ANC ≥ 1.5 × 109/L; PLT ≥ 75 × 109/L;&#xD;
&#xD;
               2. Biochemical examination need to meet the following criteria: TBIL ≤ 1.5 × ULN&#xD;
                  (upper limit of normal); ALT and AST ≤ 3 × ULN; if there is liver metastasis, ALT&#xD;
                  and AST ≤ 5 × ULN; serum Cr ≤ 1 × ULN;&#xD;
&#xD;
               3. cardiac function: LVEF ≥ 50%&#xD;
&#xD;
         12. The subject voluntarily joined the study and signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled central nervous system metastasis (defined as symptoms or requiring&#xD;
             glucocorticoids or mannitol to control symptoms);&#xD;
&#xD;
          2. Clinically symptomatic third space effusion, pericardial effusion, pleural effusion&#xD;
             and abdominal effusion that cannot be controlled by pumping or other treatments;&#xD;
&#xD;
          3. Currently or recently (within 30 days before enrollment) is participating in another&#xD;
             clinical study;&#xD;
&#xD;
          4. Five Other malignant tumors (except adequately treated cervical carcinoma in situ or&#xD;
             skin squamous cell carcinoma or controlled skin basal cell carcinoma) within the past&#xD;
             4 years;&#xD;
&#xD;
          5. Uncontrolled cardiac clinical symptoms or diseases, such as: (1) NYHA grade 2 or&#xD;
             higher heart failure (2) unstable angina pectoris (3) myocardial infarction within 1&#xD;
             year (4) clinically significant supraventricular or ventricular arrhythmias requiring&#xD;
             treatment or intervention (5) QTc &gt; 470 ms;&#xD;
&#xD;
          6. Hyperactive/venous thrombotic events, such as cerebrovascular accidents (including&#xD;
             transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous&#xD;
             thrombosis and pulmonary embolism;&#xD;
&#xD;
          7. He following history 24 days before signing the ICF: gastrointestinal ulcers,&#xD;
             gastrointestinal perforation, corrosive esophagitis or gastritis, inflammatory bowel&#xD;
             disease or inflammation, abdominal fistula, tracheoesophageal fistula or&#xD;
             intra-abdominal abscess;&#xD;
&#xD;
          8. Factors that significantly affect oral drug absorption, such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction;&#xD;
&#xD;
          9. Patients with a clear history of allergy, Potential allergy or intolerance to&#xD;
             cidaniline, fluzoparib, and carreizumab;&#xD;
&#xD;
         10. Human immunodeficiency virus (HIV) infection, active hepatitis B (hepatitis B surface&#xD;
             antigen positive and HBV DNA ≥ 500 IU/ml), hepatitis C (hepatitis C antibody positive&#xD;
             and HCV-RNA above the lower limit of detection of the analytical method);&#xD;
&#xD;
         11. Female patients during pregnancy and lactation, female patients of childbearing&#xD;
             potential with positive baseline pregnancy test or female patients of childbearing age&#xD;
             who are unwilling to take effective contraceptive measures throughout the trial;&#xD;
&#xD;
         12. According to the investigator's judgment, the presence of concomitant diseases&#xD;
             (including but not limited to hypertension with poor drug control, severe diabetes,&#xD;
             neurological or psychiatric diseases, active infection, etc.) or any other condition&#xD;
             that seriously endangers the subject's safety, may confound the study results, or&#xD;
             affect the subject's completion of this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunfang Hao</last_name>
    <phone>18622223686</phone>
    <email>haochf@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SILU WANG</last_name>
    <phone>18559171530</phone>
    <email>wangsiluaaron@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunfang Hao</last_name>
      <phone>18622223686</phone>
      <email>haochf@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Silu Wang</last_name>
      <phone>18559171530</phone>
      <email>wangsiluaaron@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

